Ingevity (NGVT) 주식 개요
Ingevity Corporation은 북미, 아시아 태평양, 유럽, 중동, 아프리카 및 남미에서 활성탄 제품, 파생 특수 화학 제품 및 엔지니어링 폴리머를 제조 및 판매합니다. 자세히 보기
NGVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorCA$5.07FV • 68.6% 저평가 내재 할인율
4849.4%Revenue growth p.a.
13.3k
37
1
270
Ingevity Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$76.19 |
| 52주 최고가 | US$77.62 |
| 52주 최저가 | US$32.72 |
| 베타 | 1.27 |
| 1개월 변동 | 6.96% |
| 3개월 변동 | 15.81% |
| 1년 변동 | 128.94% |
| 3년 변동 | 18.31% |
| 5년 변동 | -11.82% |
| IPO 이후 변동 | 183.66% |
최근 뉴스 및 업데이트
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Recent updates
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
Sep 30
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Sep 06Ingevity: No Specialty Play, Awaiting External Drivers
Sep 05Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jun 27Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
May 28Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Apr 05Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Feb 20Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jan 16What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Nov 07Is Ingevity (NYSE:NGVT) A Risky Investment?
Oct 13Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
Sep 08Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Aug 27Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 03Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
Jul 13Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Jun 14Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Apr 18Is Ingevity (NYSE:NGVT) A Risky Investment?
Mar 22What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?
Jan 23Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares
Jan 04These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts
Nov 10주주 수익률
| NGVT | US Chemicals | US 시장 | |
|---|---|---|---|
| 7D | 1.2% | -0.5% | 0.6% |
| 1Y | 128.9% | 12.6% | 28.7% |
수익률 대 산업: NGVT은 지난 1년 동안 12.6%의 수익을 기록한 US Chemicals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: NGVT은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| NGVT volatility | |
|---|---|
| NGVT Average Weekly Movement | 4.7% |
| Chemicals Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
안정적인 주가: NGVT는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: NGVT의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1964 | 1,500 | David Li | www.ingevity.com |
Ingevity Corporation은 북미, 아시아 태평양, 유럽, 중동, 아프리카 및 남미에서 활성탄 제품, 파생 특수 화학 제품 및 엔지니어링 폴리머를 제조 및 판매하는 회사입니다. 이 회사는 세 가지 부문으로 운영됩니다: 성능 소재, 성능 화학, 첨단 폴리머 기술입니다. 퍼포먼스 소재 부문은 자동차, 트럭, 오토바이, 보트의 가솔린 증기 배출 제어 시스템에 사용되는 경목 기반 및 화학 활성탄 제품을 엔지니어링, 제조 및 판매합니다.
Ingevity Corporation 기초 지표 요약
| NGVT 기초 통계 | |
|---|---|
| 시가총액 | US$2.57b |
| 순이익 (TTM) | -US$150.30m |
| 매출 (TTM) | US$1.17b |
2.3x
주가매출비율(P/S)-17.9x
주가수익비율(P/E)NGVT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| NGVT 손익계산서 (TTM) | |
|---|---|
| 매출 | US$1.17b |
| 매출원가 | US$706.10m |
| 총이익 | US$461.50m |
| 기타 비용 | US$611.80m |
| 순이익 | -US$150.30m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
May 06, 2026
| 주당순이익(EPS) | -4.27 |
| 총이익률 | 39.53% |
| 순이익률 | -12.87% |
| 부채/자본 비율 | 3,736.4% |
NGVT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/04/30 09:27 |
| 종가 | 2026/04/30 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Ingevity Corporation는 8명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |